Fluconazole is a new triazole antifungal drug with a broad-spectrum antifungal effect and can selectively inhibit fungal sterol synthesis. It is effective against Candida infection, Cryptococcus neoformans infection, Malassezia sacchariflora, Microsporum, Trichophyton, Epidermophyton, Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum, Peyer's staining bacteria, and Cladosporium carinii. It has a highly selective inhibitory effect on fungal cytochrome p-450-dependent enzymes.

This product is a broad-spectrum semi-synthetic cephalosporin antibiotic. Its activity against penicillinase-producing Staphylococcus aureus, group A hemolytic streptococci, viridans streptococci and Staphylococcus epidermidis is the same as that of cefadroxil, and its antibacterial effect against non-enzyme-producing Staphylococcus aureus and pneumococci is 2 to 4 times stronger than that of cefadroxil. Its activity against Gram-negative bacilli, including Escherichia coli and Klebsiella pneumoniae, is stronger than that of cefadroxil, and is similar to that of cefadroxil. Its activity against Proteus mirabilis, Salmonella and Shigella is stronger than that of cefadroxil. 2.9 to 8 mg/L of this product can inhibit all Haemophilus influenzae, including strains resistant to ampicillin. Moraxella catarrhalis and Neisseria gonorrhoeae are very sensitive to this product. Indole-positive Proteus, Serratia, Acinetobacter and Pseudomonas aeruginosa are all resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls.

By inhibiting bacterial transpeptidase, it prevents the synthesis of bacterial cell walls, inhibits or kills bacteria; when used with trimethoprim, it improves antibacterial ability, delays the development of drug resistance, and reduces oral doses

By inhibiting bacterial transpeptidase, it prevents the synthesis of bacterial cell walls, inhibits or kills bacteria; when used with cephalexin, it can improve antibacterial ability, delay the development of drug resistance, and reduce oral dosage

This product is a broad-spectrum semi-synthetic penicillin with extremely low toxicity. The antibacterial spectrum is similar to that of penicillin, and it has a strong antibacterial effect on grass-green streptococci, hemolytic streptococci, and enterococci. Diphtheria bacillus, anthrax bacillus, Gram-positive anaerobic cocci and bacilli are sensitive to this product; meningococci, pertussis bacilli, and Brucella are also very sensitive. Escherichia coli, Salmonella, Shigella dysenteriae, Proteus, influenza bacilli, pneumococci, gonococci, etc., all have varying degrees of drug resistance because some strains produce beta-lactamase. Among them, the resistance rate of Escherichia coli is as high as 50-60%. Enterobacter bacteria, Pseudomonas aeruginosa, and anaerobic Gram-negative bacilli are resistant to this product. This product is mainly used to treat infectious diseases caused by sensitive Staphylococcus aureus, hemolytic streptococci, gonococci, meningococci and diphtheria Bordetella, pertussis Bordetella, influenza Bordetella, Salmonella, Shigella, etc.; such as respiratory tract infections (pneumonia, acute and chronic bronchitis, whooping cough, etc.), gastroenteritis and digestive tract infections (liver and gallbladder infections, acute and chronic gastroenteritis, bacillary dysentery, typhoid and paratyphoid, etc.), urinary tract infections (gonorrhea, urethritis, cystitis, etc.), soft tissue infections and sepsis, meningitis, endocarditis, etc.

It is a semi-synthetic broad-spectrum penicillin antibiotic that mainly acts on the bacterial reproduction stage by inhibiting the biosynthesis of cell wall mucopolypeptides. It is effective against many Gram-positive and Gram-negative bacteria.

It has a β-lactam structure similar to penicillin and has only weak antibacterial activity itself, but it can inactivate enzymes produced by many bacteria by blocking the active site of β-lactamase, especially for clinically important plasmid-mediated β-lactamase. It can protect amoxicillin from hydrolysis and destruction by β-lactamase, so it is still effective against resistant bacteria that produce β-lactamase.